Zinc-doped copper oxide nanocomposites reverse temozolomide resistance in glioblastoma by inhibiting AKT and ERK1/2

Ning Wu; Chunyun Zhang; Changhui Wang; Lairong Song; Weicheng Yao; Aharon Gedanken; Xiukun Lin; Dayong Shi

doi:10.2217/nnm-2017-0359

Zinc-doped copper oxide nanocomposites reverse temozolomide resistance in glioblastoma by inhibiting AKT and ERK1/2

Ning Wu, Chunyun Zhang, Changhui Wang, Lairong Song, Weicheng Yao, Aharon Gedanken, Xiukun Lin, Dayong Shi

Department of Chemistry

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Aim: To assess the effect of zinc-doped copper oxide nanocomposites (nZn-CuO NPs) on glioblastoma therapy.Materials & methods: NZn-CuO NPs were synthesized by sonochemical method and its antitumor effects and underlying molecular mechanisms were investigated both in vitro and in vivo. Results: After nZn-CuO NPs treatment, cell proliferation was significantly inhibited in dividing cancer cells but less toxicity was observed in normal cells. In vivo studies show that nZn-CuO NPs inhibited tumor growth in a dose-dependent manner. Further study found that nZn-CuO NPs trigger cell reactive oxygen species (ROS) generation and intrinsic apoptotic pathway. In temozolomide resistance glioblastoma, nZn-CuO NPs disturb cell growth and sphere formation by inhibiting AKT and ERK1/2 activation. Conclusion: NZn-CuO NPs possess the potential to be developed as a novel anti-tumor agent, especially to treat temozolomide resistance glioblastoma.

Original language	English
Pages (from-to)	1303-1318
Number of pages	16
Journal	Nanomedicine
Volume	13
Issue number	11
DOIs	https://doi.org/10.2217/nnm-2017-0359
State	Published - Jun 2018

Bibliographical note

Publisher Copyright:
© 2018 Future Medicine Ltd.

Funding

This work was supported by the key research and development project of Shandong province (2016GSF115009) and key research program of Frontier Sciences, CAS (QYZDB-SSW-DQC014) and partly supported by NSFC Shandong Provincial Natural Science Foundation (grant number ZR2014HM004) and Qingdao National Laboratory for Marine Science and Technology (number 2015ASKJ02), and Aoshan Talents Program Supported by Qingdao National Laboratory for Marine Science and Technology (number 2015ASTP). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Funders	Funder number
Aoshan Talents Program	2015ASTP
NSFC Shandong Provincial Natural Science Foundation	ZR2014HM004
Chinese Academy of Sciences	QYZDB-SSW-DQC014
Qingdao National Laboratory for Marine Science and Technology	2015ASKJ02
key research and development project of Shandong province	2016GSF115009

Keywords

AKT
ERK1/2
apoptosis
cancer/oncology
glioblastoma
metal nanoparticles
temozolomide resistance
therapeutics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/nnm-2017-0359

Cite this

@article{73292bedb1314dfa8e7f12d4943c7970,

title = "Zinc-doped copper oxide nanocomposites reverse temozolomide resistance in glioblastoma by inhibiting AKT and ERK1/2",

abstract = "Aim: To assess the effect of zinc-doped copper oxide nanocomposites (nZn-CuO NPs) on glioblastoma therapy.Materials & methods: NZn-CuO NPs were synthesized by sonochemical method and its antitumor effects and underlying molecular mechanisms were investigated both in vitro and in vivo. Results: After nZn-CuO NPs treatment, cell proliferation was significantly inhibited in dividing cancer cells but less toxicity was observed in normal cells. In vivo studies show that nZn-CuO NPs inhibited tumor growth in a dose-dependent manner. Further study found that nZn-CuO NPs trigger cell reactive oxygen species (ROS) generation and intrinsic apoptotic pathway. In temozolomide resistance glioblastoma, nZn-CuO NPs disturb cell growth and sphere formation by inhibiting AKT and ERK1/2 activation. Conclusion: NZn-CuO NPs possess the potential to be developed as a novel anti-tumor agent, especially to treat temozolomide resistance glioblastoma.",

keywords = "AKT, ERK1/2, apoptosis, cancer/oncology, glioblastoma, metal nanoparticles, temozolomide resistance, therapeutics",

author = "Ning Wu and Chunyun Zhang and Changhui Wang and Lairong Song and Weicheng Yao and Aharon Gedanken and Xiukun Lin and Dayong Shi",

note = "Publisher Copyright: {\textcopyright} 2018 Future Medicine Ltd.",

year = "2018",

month = jun,

doi = "10.2217/nnm-2017-0359",

language = "אנגלית",

volume = "13",

pages = "1303--1318",

journal = "Nanomedicine",

issn = "1743-5889",

publisher = "Taylor and Francis Ltd.",

number = "11",

}

TY - JOUR

T1 - Zinc-doped copper oxide nanocomposites reverse temozolomide resistance in glioblastoma by inhibiting AKT and ERK1/2

AU - Wu, Ning

AU - Zhang, Chunyun

AU - Wang, Changhui

AU - Song, Lairong

AU - Yao, Weicheng

AU - Gedanken, Aharon

AU - Lin, Xiukun

AU - Shi, Dayong

PY - 2018/6

Y1 - 2018/6

N2 - Aim: To assess the effect of zinc-doped copper oxide nanocomposites (nZn-CuO NPs) on glioblastoma therapy.Materials & methods: NZn-CuO NPs were synthesized by sonochemical method and its antitumor effects and underlying molecular mechanisms were investigated both in vitro and in vivo. Results: After nZn-CuO NPs treatment, cell proliferation was significantly inhibited in dividing cancer cells but less toxicity was observed in normal cells. In vivo studies show that nZn-CuO NPs inhibited tumor growth in a dose-dependent manner. Further study found that nZn-CuO NPs trigger cell reactive oxygen species (ROS) generation and intrinsic apoptotic pathway. In temozolomide resistance glioblastoma, nZn-CuO NPs disturb cell growth and sphere formation by inhibiting AKT and ERK1/2 activation. Conclusion: NZn-CuO NPs possess the potential to be developed as a novel anti-tumor agent, especially to treat temozolomide resistance glioblastoma.

AB - Aim: To assess the effect of zinc-doped copper oxide nanocomposites (nZn-CuO NPs) on glioblastoma therapy.Materials & methods: NZn-CuO NPs were synthesized by sonochemical method and its antitumor effects and underlying molecular mechanisms were investigated both in vitro and in vivo. Results: After nZn-CuO NPs treatment, cell proliferation was significantly inhibited in dividing cancer cells but less toxicity was observed in normal cells. In vivo studies show that nZn-CuO NPs inhibited tumor growth in a dose-dependent manner. Further study found that nZn-CuO NPs trigger cell reactive oxygen species (ROS) generation and intrinsic apoptotic pathway. In temozolomide resistance glioblastoma, nZn-CuO NPs disturb cell growth and sphere formation by inhibiting AKT and ERK1/2 activation. Conclusion: NZn-CuO NPs possess the potential to be developed as a novel anti-tumor agent, especially to treat temozolomide resistance glioblastoma.

KW - AKT

KW - ERK1/2

KW - apoptosis

KW - cancer/oncology

KW - glioblastoma

KW - metal nanoparticles

KW - temozolomide resistance

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85049123656&partnerID=8YFLogxK

U2 - 10.2217/nnm-2017-0359

DO - 10.2217/nnm-2017-0359

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 29949469

AN - SCOPUS:85049123656

SN - 1743-5889

VL - 13

SP - 1303

EP - 1318

JO - Nanomedicine

JF - Nanomedicine

IS - 11

ER -

Zinc-doped copper oxide nanocomposites reverse temozolomide resistance in glioblastoma by inhibiting AKT and ERK1/2

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this